María J. Blanco Prieto

Dr. María J. Blanco Prieto

Universidad de Navarra. Department of Pharmaceutical Technlology and chemistry
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2013 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
CTCristina Tamames-Tabar
Cristina Tamames-Tabar
DCDenise Cunha
Denise Cunha
EIEdurne Imbuluzqueta
Edurne Imbuluzqueta
FRFlorence Ragon
Florence Ragon
CSChristian Serre
Christian Serre
PHPatricia Horcajada
Patricia Horcajada
A series of fourteen porous Metal–Organic Frameworks (MOFs) with different compositions (Fe, Zn, and Zr; carboxylates or imidazolates) and structures have been successfully synthesised at the nanoscale and fully characterised by XRPD, FTIR, TGA, N2 porosimetry, TEM, DLS and ζ-potential. Their toxicological assessment was performed using two different cell lines: human epithelial cells from foetal cervical carcinoma (HeLa) and murine macrophage cell line (J774). It appears that MOF nanoparticles (NPs) exhibit low cytotoxicity, comparable to those of other commercialised nanoparticulate systems, the less toxic being the Fe carboxylate and the more toxic being the zinc imidazolate NPs. The cytotoxicity values, higher in J774 cells than in HeLa cells, are mainly function of their composition and cell internalisation capacity. Finally, cell uptake of one of the most relevant Fe-MOF-NPs for drug vectorisation has been investigated by confocal microscopy studies, and indicates a faster kinetics of cell penetration within J774 compared to HeLa cells.

1 January 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
MWMing Ming Wen
Ming Ming Wen
NENoha S. El-Salamouni
Noha S. El-Salamouni
WEWessam M. El-Refaie
Wessam M. El-Refaie
HHHeba A. Hazzah
Heba A. Hazzah
MAMai M. Ali
Mai M. Ali
Amira HanafyAmira Hanafy
Amira Hanafy

1 October 2010 in Journal of Controlled Release
Verified
Journal Article
Closed access
Fabio Rocha FormigaFabio Rocha Formiga
Fabio Rocha Formiga
BPBeatriz Pelacho
Beatriz Pelacho
Elisa Garbayo AtienzaElisa Garbayo Atienza
Elisa Garbayo Atienza
GAGloria Abizanda
Gloria Abizanda
JGJuan J Gavira
Juan J Gavira
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto

13 June 2014 in CrystEngComm
Verified
Journal Article
Closed access
PDF file
CTC. Tamames-Tabar
C. Tamames-Tabar
EIE. Imbuluzqueta
E. Imbuluzqueta
NGN. Guillou
N. Guillou
CSChristian Serre
Christian Serre
SMS. R. Miller
S. R. Miller
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto
A novel biocompatible and bioactive Metal–Organic Framework (BioMOF), named BioMIL-5 (Bioactive Materials from Institut Lavoisier), was hydrothermally synthesized from a Zn2+ salt and azelaic acid, both with interesting antibacterial and dermatological properties. Its structure was determined by high resolution X-ray powder diffraction, and further characterized by infrared spectroscopy, thermogravimetric analysis and elemental analysis. The determination of the minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values of BioMIL-5 in Staphylococcus aureus and Staphylococcus epidermidis demonstrated that the antimicrobial activity of the individual components of BioMIL-5 were maintained after its synthesis. Moreover, BioMIL-5 was found to be stable in water and in bacterial culture medium, especially in water, leading to the subsequent progressive release of its active constituents, AzA and Zn2+ ions. Interestingly, this slow active delivery allowed control of the growth of a S. epidermidis suspension over 7 days. The high stability of this material and the maintenance of its antibacterial properties make BioMIL-5 a good candidate for future bioapplications, for skin care and in cosmetics.

1 April 2009 in Journal of Controlled Release
Verified
Journal Article
Closed access
Elisa Garbayo AtienzaElisa Garbayo Atienza
Elisa Garbayo Atienza
CMC.N. Montero-Menei
C.N. Montero-Menei
EAEduardo Ansorena
Eduardo Ansorena
Jose L. LanciegoJose L. Lanciego
Jose L. Lanciego
MAMaria S Aymerich
Maria S Aymerich
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto

1 May 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LSLaura Saludas
Laura Saludas
SPSimon Pascual-Gil
Simon Pascual-Gil
FPFelipe Prosper
Felipe Prosper
Elisa Garbayo AtienzaElisa Garbayo Atienza
Elisa Garbayo Atienza
María J. Blanco PrietoMaría J. Blanco Prieto
María J. Blanco Prieto